Monthly Archives: April 2012

Eurand et al. (“Cephalon”) v. Mylan Pharmaceuticals, Inc. et al.

Posted on April 20, 2012 by Patrick J. Halloran, Ph.D., J.D.

Docket No. 2011-1399, -1409 NEWMAN, O’MALLEY, REYNA April 16, 2012 Subject matter: ANDA/generics, obviousness Brief summary: Bioequivalence parameters are not necessarily obvious, and “therapeutically effective” claims may prove very valuable. Best mode may not be found where there is enablement. … Continue reading →

Posted in Best mode, Generics / ANDA, Obviousness | Leave a comment

Bayer Schering et al. v. Lupin Ltd. et al.

Posted on April 18, 2012 by Patrick J. Halloran, Ph.D., J.D.

Docket No. 2011-1143, -1228 NEWMAN (D), PLAGER, BRYSON April 16, 2012 Subject matter: ANDA, generics Brief Summary: An ANDA may not infringe an Orange Book method of use patent where the claims do not exactly track the use approved by … Continue reading →

Posted in Generics / ANDA | Leave a comment

Ergo Licensing, LLC et al. vs. Carefusion 303, Inc.

Posted on April 3, 2012 by Patrick J. Halloran, Ph.D., J.D.

Docket No. 2011-1229 NEWMAN(D), LINN, MOORE March 26, 2012 Brief summary: Computer-related means-plus-function claims typically must include an algorithm for carrying out the claimed function. Summary: The Federal Circuit affirmed a DC finding that Ergo’s claims were indefinite because no … Continue reading →

Posted in Indefiniteness | Leave a comment